Manchester University NHS Foundation Trust, Manchester; 4 Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK Background: There has been recent systematic review of key evidence in psychosocial intervention in autism but little review of biological treatments. Methods: We analyse the current literature from the perspective of intervention and mechanism targets across social and biological development. Results: The overall quality of trials evidence in autism intervention remains relatively low, despite some recent progress. Many treatments in common use have little or no evidence base. This is very concerning in such an important disorder. A variety of psychosocial interventions can show effect to improve some short-term effects on children's immediate dyadic social interactions, for instance with caregivers. But showing true effectiveness in this developmental disorder requires generalisation of such effects into wider social contexts, on autism symptoms and in long-term progress in development. Only a few interventions so far have begun to show this. A number of early phase interventions on biological targets have shown real promise, but none has yet progressed to larger scale effectiveness trials on behavioural or symptom outcomes. Conclusions: There has been enough progress in psychosocial intervention research now to be able to begin to identify some evidence-based practice in autism treatment. To consolidate and improve outcomes, the next phase of intervention research needs improved trial design, and an iterative approach building on success. It may also include the testing of potential synergies between promising biological and psychosocial interventions.
Introduction
A recent systematic review by French and Kennedy (2018) gives a methodologically rigorous summary of the key evidence for psychosocial interventions in autism. The purpose of this current research review is complimentary. First, we provide analysis and commentary on what the evidence such as reviewed by French and Kennedy (2018) represents for the current state of autism intervention science as a whole, in terms of methodological developments, implicit or explicit intervention targets and common factors in treatment. We focus particularly on intervention and mechanism targets in order to provide a clarifying and unifying thread with which to compare evidence across different interventions, to establish precisely what overall progress has been made, and what has been learnt about autism as a developmental condition from intervention research. We aim for this to point a way forward systematically to new and refined mechanism targets in future.
Next, we extend the focus on mechanism to bridge between intervention work targeting psychosocial development and emerging work on complimentary neural system targets. These two domains are usually considered separately; it is the thesis of this review that considering them together now at a mechanism level is timely. It points the way forward to a new phase of autism intervention science addressing potential synergies between psychological and biological intervention strategies in this neurodevelopmental disorder.
Progress in psychosocial intervention research

Trial methods
An immediately striking feature of the contemporaneous systematic review by French and Kennedy (2018) is how few of the studies they identified met basic Cochrane quality criteria for absence of risk of bias (in just six trials out of the 48 that met their inclusion criteria, even though most had been conducted in the last few years). Another is how chaotic the autism intervention field is internationally, with those 48 trials testing no less than 34 different models of intervention, usually in underpowered small N trials from single sites.
While there has been substantive progress in recent years, it remains striking and paradoxical that the intervention science in such an important developmental disorder continues to be so fragmented and methodologically fragile. This cannot just be put down to lack of funding. The majority of interventions tested have been behavioural or psychosocial, areas in which there has been debate (historically but also currently) as to the appropriateness or viability of conducting rigorous trials. Any doubts as to the value and importance of Randomised Controlled Trials (RCT) methodology in this area however should have been laid to rest. It turns out that they are not only feasible but can have great advantages in clarifying and adjusting for the many potential confounds involved in properly testing complex interventions within an equally complex phenotype (Dunn et al., 2015) . It has been a genuine achievement for the field (in parallel certainly with other areas of psychosocial treatment research) to have demonstrated the value of RCT methods and, increasingly, the implementation of CONSORT reporting standards; but the French and Kennedy (2018) review shows how patchy this has been in practice. Enormous sums of public and private money are spent in health care systems across the world on interventions that have no rigorous evidence base. For instance, probably the most ubiquitous interventions globally (under the umbrella of Early Intensive Behavioural Intervention (EIBI) or ABA) continue to be actively promoted on the basis of single case designs alone, internationally considered to be low levels of evidence in healthcare; a Cochrane review of EIBI (Reichow, Barton, Boyd, & Hume, 2012) found only one historical, small and equivocal RCT and the situation has not changed subsequently. Consequently, such interventions and others do not feature at all in the French and Kennedy (2018) review or in relevant guidance such as UK NICE (National Institute for Health & Care Excellence, 2013) . This is a truly troubling situation given the high profile and importance of autism in public health, and its economic and social costs. On just one metric, the life span economic cost of autism per individual has been estimated as up to $2.4 million in the United States and £1.5 million in the United Kingdom (Buescher, Cidav, Knapp, & Mandell, 2014; Knapp, Romeo, & Beecham, 2009 ), higher than asthma or diabetes. The reader might imagine if international clinical practice in these latter conditions was underpinned in this way.
In a further paradox, the autism field actually has a significant advantage over some other areas of psychosocial intervention research in having developed relatively valid, predictive and blind-codable measures of social interaction and autism symptom outcomes; something that has often been elusive in other areas. Lack of assessment blinding in self-or informant-reporting can seriously inflate treatment effect estimates, especially in trials without participant blinding to treatment, inevitably the norm in most psychosocial treatments (Sonuga-Barke et al., 2013) . In addition to incorporation of common blinded outcomes, a further key next step in methodological development will be widespread implementation of pre-recruitment trial registration and pre-specification of analysis plans and primary outcomes, avoiding the post hoc selective reporting of multiple measured outcomes that has often been the norm. At a stroke this discipline, although arduous initially, would transform the validity and salience of the trial reporting.
A third key step will be the explicit investigation of mechanism, which will allow an iterative evolution towards more refined treatments (Green, 2015; Kraemer, Wilson, Fairburn, & Agras, 2002) . The first part of this review consequently builds on French and Kennedy (2018) by focusing on the (explicit or implicit) mechanisms and treatment targets within the variety of treatments tested to date -particularly in those studies reviewed by French and Kennedy (2018) as having relatively low risk of bias. We aim through this to provide a unifying view of the current research along with an agenda for moving forward with new and refined mechanism targets. We then point the way forward to some of these new potential targets in brain science in the second part of the review.
Co-construction of outcome targets
A further achievement for autism intervention has been an emerging dialogue with user groups, advocates and families towards coconstructing relevant outcome variables and outcome targets after intervention. Autism has benefitted from active debates and dialogue between these groups, which should be creative for future progress. At the extreme some advocates object to any idea of intervention at all as impacting negatively on 'autism identity', wanting instead a focus on acceptance, social rights and associated mental health. These latter objectives are of undeniable importance, but the review below addresses how interventions, theoretically targeted at core early developmental processes, can impact positively on key autism features and adaptation, even in this highly heritable neurodevelopmental disorder. This empirical evidence, alongside early diagnosis, forms the ethical case for intervention; but the outcomes selected do need to be of shared relevance. This is a theme we return to at the end of the review.
Targets and mechanisms in psychosocial autism intervention
Parent-child dyadic interaction as a foundation for social development
The rationale for targeting early parent-child social interaction (PCI) in autism as a social impairment disorder comes from decades of child development research suggesting the foundational value of positive early dyadic social interaction for later child social communication and adaptation (Landry, young children at risk of or diagnosed with the condition. Thus increased parent directiveness (but not reduced responsiveness) is found in the latter part of the first year in infant siblings at risk of autism (Harker, Ibanez, Nguyen, Messinger, & Stone, 2016; Wan et al., 2013) along with reduced child attentiveness to parent, affective signalling and coordinated dyadic communication (Parlade & Iverson, 2015; Wan et al., 2013) . Similar patterns are seen in established autism as well as in other developmental disabilities (Blacher, Baker, & Kaladjian, 2013; Doussard-Roosevelt, Joe, Bazhenova, & Porges, 2003) . We cannot of course assume that such patterns of PCI are responsible for autism outcomes; it could be in theory that these different PCI trajectories are incidental or even adaptive (Mottron, 2017) . Nevertheless, a transactional account (Sameroff, 2009 ) of the early reciprocal interplay between intrinsic developmental atypicalities in autism and the early social environment would suggest that evoked perturbations in interaction can indeed serve to amplify social impairments and symptom impact over time; on this basis, reversing these deficits and optimising ('normalising') social interaction could in theory improve social functioning or reduce symptoms in autistic children. The PCI target has the added theoretical advantage of being 'naturalistic' (i.e. working with the everyday developmental/family system of the child) and potentially more easily generalisable than clinic-based interventions directly with the child. It is however also based on the assumption that intervening in the developmental system in this way will be 'powerful' enough significantly to impact autism development, traditionally seen to be intrinsic and relatively environmentally stable. Whether this assumption holds is an empirical question to which we will return.
Interventions designed to impact PCI have often used demonstration and modelling by the therapist working directly with the child in the parent's presence or mixed with didactic education. More recently, there has been a rise in more exclusive work with the parent using direct coaching in realtime during interaction or use of video-feedback techniques. The precise 'proximal' intervention targets within PCI (that is, the immediate goal for change with intervention) have varied from parental 'responsiveness' and 'non-directiveness', parental 'communicative synchrony', to mutual 'joint attention and engagement' and 'affect sharing' (see Figure 1) . Each of these targets implies a slightly different theoretical orientation and defined goals.
Parental responsiveness and non-directiveness. The concept of parental responsiveness is often associated with early relational research, but terms are used subtly differently between groups. These aspects of PCI are typically coded with global measures such as Maternal Behavior Rating Scale (Mahoney, Powell, & Finger, 1986) , Manchester Assessment of Caregiver Infant interaction (MACI; (Wan, Brooks, Green, Abel, & Elmadih, 2017) , Emotional Availability Scale (EAS; Biringen, Derscheid, Vliegen, Closson, & Easterbrooks, 2014) , but also with event-sampling (Kasari, Siller, et al., 2014) .
Two recent studies in the French and Kennedy (2018) review found treatment effects on parent 'responsiveness' in autism. A 12 week 'Focused Playtime Intervention' (FPI) that combined live modelling from therapist to parent with video-feedback and psycho-education was tested in a pre-emptive study of 66 toddlers at high autism-risk mean age 22 months (Kasari, Siller et al., 2014) . It found a positive endpoint effect on level of parental responsiveness, but the effect was not sustained at 3 months follow up nor associated with effect on child variables (language scores, joint attention or child communication, diagnostic outcome). A 10-week Joint attention, Symbolic Play, Engagement and Regulation (JASPER) intervention also produced proximal effect on responsiveness in an RCT of 86 toddlers with diagnosed autism spectrum disorders (ASD) (22-36 months) against psycho-education, here associated with improved child-initiated joint engagement with parent (Kasari, Gulsrud, Paparella, Hellemann, & Berry, 2015; Shire et al., 2017) . In contrast, a parent-mediated version of the behaviour-learning focused Early Start Denver Model (ESDM) using therapist direct coaching and modelling for parents in 98 children in a 12 week waitlist controlled trial, found no effect on responsiveness or other parent interaction or child outcome (Rogers et al., 2012) . Initial report of the subsequent 3 site trial of ESDM on this cohort also found no overall group effect (Rogers et al., 2014) , so prior parent coaching did not appear to enhance subsequent therapist-mediated treatment.
Studies of interventions using other methods have found effects on non-directiveness but not responsiveness. A 3 month six session video-feedback intervention (VIPP-AUTI) tested against home-based nursing care in 78 children with ASD aged 16-61 months (Poslawsky et al., 2015) found a treatment effect on reduced parental 'intrusiveness' in dyadic interaction at endpoint but no effect on parent sensitivity or structuring. Child effects on initiation of joint attention (but not other aspects of behaviour) were found at 3-month follow up, although not associated with the prior parent change. A separate 12-session 'iBASIS-VIPP' intervention was tested in a pre-emptive RCT for infants at familial autism-risk against no intervention in 54 dyads, and found to have good effect at 15-month endpoint in reducing parent non-directiveness, but no effect on responsiveness; there was associated improvement in child attentiveness to parent . Two-year follow up of this trial showed sustained improvement in parent non-directiveness 1 year after treatment but evidence of fall-off thereafter, although improvement in child communication initiation with parent and prodromal symptoms was sustained (see below).
Parent communicative synchrony. The concept of synchrony is allied to 'responsiveness' but derived more from the communication development literature, predicting communication and language outcomes in autism (Siller & Sigman, 2002) and usually measured using event-sampling rather than global rating. Subtle differences in the way this behaviour is conceptualised and measured again hamper comparison across treatments at a detailed mechanism level. Thus, one definition is of 'parental verbal behaviour directed to the child's focus of attention and actions' (i.e. child-focused behaviours) (Siller, Hutman, & Sigman, 2013) , and another is of 'parent communication responses that acknowledge, confirm or reinforce the child's focus, play, actions, thoughts or intentions; in tune with what the child is thinking, saying or doing rather than redirecting the child away from his play, thoughts or communication' (Aldred, Green, Emsley, & McConachie, 2012) .
Parental synchrony has been targeted particularly by the video-feedback Preschool Autism Communication (PACT) treatment, which targets social interaction and communication impairments, first by increasing parental sensitivity to child communication and reducing mistimed responses using videofeedback, and second by promoting a range of positive social communication strategies. PACT was tested in an RCT of 152 children with core autism (age 2-5 years), which found large endpoint effect in optimising parental synchrony across three geographically varied contexts in the United Kingdom (Green et al., 2010; Pickles et al., 2016) . The same effect was replicated in an RCT testing adaptation of PACT to South Asia in 64 children aged 2-9 years (Rahman et al., 2016) . The FPI intervention as above, also partially video-aided, found small gains in parental synchrony confined to dyads with more language-delayed children (Siller et al., 2013) .
Joint engagement and Joint attention. An alternative target for treatment is the quality of shared interaction rather than the separate behaviour of each partner. Typically, this will be measured as 'duration' counts of the phenomenon of interest from video-tape and like all these methods importantly can be coded blind to treatment allocation. 'Joint engagement' as an outcome is a particular feature of the JASPER model and a number of trials have shown reliable increases in joint engagement or joint attention following relatively brief (usually 12 week) treatments. Typically, the caregivers are coached in the treatment model, encouraged to use strategies for setting up the learning environment, modelling and prompting for joint attention, expanding play, and using developmentally appropriate language. For instance, Kasari, Lawton et al. (2014) ; randomised 147 'low-resourced' families of a child diagnosed with ASD, aged 24-60 months, to either a caregiver-mediated intervention (CMM) following the 12-week JASPER treatment and involving the child, or a group caregiver-only education programme. Significant interaction between treatment group and time during treatment was identified on the primary outcome of Joint Engagement, with the caregiver-mediated group exhibiting a significantly greater rate of improvement. Both groups also demonstrated improvement in joint attention, but not in functional play. Chang, Shire, Shih, Gelfand, & Kasari (2016) randomly assigned 66 children with ASD aged 36-60 months to a teacher-delivered JASPER intervention or wait-list control. Endpoint intervention effects were reported for a number of the multiple measured outcomes, including childinitiated joint engagement and joint attention, receptive language, but not on others such as expressive language or symbolic play. However, a qualification would have to be that this interpretation did not adjust for the multiple testing. A third study (Landa, Holman, O'Neill, & Stuart, 2011 ) randomly assigned 50 children, aged 21-33 months with a diagnosis of ASD, to parent education and parent education supplemented with a group focusing on 'Interpersonal Synchrony' within a supplementary social curriculum. Intervention took place for two-and-ahalf hours a day, 4 days per week, for 6 months. A significant treatment effect was found for socially engaged imitation, with a large increase (17%-42%) in imitated acts paired with eye contact in the Interpersonal Synchrony group (Landa et al., 2011) . A caveat is that these outcomes were collected within the training environment and close to the trained targets of intervention. No significant between-group differences were observed for initiation of joint attention and shared positive affect, although trends were seen.
Behavioural training methods
Behavioural learning methods use focused behaviour modification techniques to influence behaviour change. In traditional behavioural interventions for autism the targets are reduction in unwanted (often repetitive or assumed non-socially functional) behaviours along with increase in identified social behaviours. In more recent studies, the targets for behavioural change are more developmentally informed; for instance, in pivotal response therapy (PRT) the targets are behaviours such as motivation for engagement and interaction considered theoretically 'pivotal' for generating wider generalised change. Broader 'curriculum' models such as Early Start Denver Model (ESDM) select a range of developmentally relevant targets, from communication to play to motor activity. What distinguishes these models however is that the methods used to achieve therapeutic change towards such targets are still taken from behavioural learning theory, largely using repetition and contingency reinforcement for desired behaviours (Koegel, Singh, Koegel, Hollingsworth, & Bradshaw, 2014) . While use of contingencies is part of naturalistic parenting, its use in these models is much more exclusive and intensively focused. Interventions of this kind are typically intensive and therapist-child delivered over several years. The only trial of this type of intervention identified by French and Kennedy (2018) as having acceptable low risk of bias was, however, of a relatively low intensity (one session/week over 12 weeks) group PRT intervention, focused on improving functional communication (Hardan et al., 2015) . The primary outcome was the frequency of functional child utterances in the dyad coded during structured lab interaction in which parents were instructed to 'try getting the child to communicate as much as possible'. Parents were rated as implementing PRT methods successfully; total child utterances increased in the PRT group, with the effect driven by imitative and non-verbally prompted utterances rather than spontaneous utterances; and verbal prompts had no effect. The pattern of this result could, however, be subject to 'training to the test'; parental contingent reinforcement of child utterances, trained in the therapy, produced local context-specific increase in the target child behaviour. Evidence for generalisation is modest; independent global impression of social communication from same tapes alongside parent interview reported improvements as did parent-reported communication on Vineland, but there was no effect in parentreported language use, standard language measures or parent-rated autism behaviours. A subsequent similar intervention model combining PRT and ABA reported effects on dyadic joint engagement and shared enjoyment but also no generalised effect (Brian, Smith, Zwaigenbaum, & Bryson, 2017) .
Summary -proximal dyadic targets
The evidence outlined above shows that caregiver dyadic behaviours with their child ( Figure 1A ) are notably responsive to a number of different interventions (just as they can be in non-autism contexts). This applies across the spectrum of social class, ethnicity and education. Replicated effects from robust trials of various interventions in autism show moderate to large effect sizes, particularly to improve parental responsiveness sensitivity and synchrony, theoretically linked in development to positive child social and communication outcomes. In relation to intervention techniques, video feedback probably has the strongest evidence for producing reliable parental change in this kind in both autism (Aldred, Green, & Adams, 2004; Green et al., 2010; Kasari, Siller et al., 2014; Poslawsky et al., 2015; Rahman et al., 2016) and neurotypical groups (Juffer, Bakermans-Kranenburg, & van IJzendoorn, 2008) . Techniques primarily using group or individual coaching and modelling techniques with parents do not show such reliable results (Carter et al., 2011; Rogers et al., 2012) . Targets involving reciprocal dyadic interaction between parent and child, such as joint engagement and joint attention (Figure 1B) have also proved treatable in replicated studies. There is less consistent evidence that the child's dyadic social interaction in turn can be improved ( Figure 1C ). Many studies demonstrating increased parental responsiveness have not found that this transmitted well into child effects; others have shown change in both parental responsiveness and child-initiated joint engagement joint attention (Shire et al., 2017) . However, focused video-feedback for parents in the PACT and iBASIS trials and a mixed coaching, modelling and video work in JASPER are all associated with reciprocal effects on spontaneous child communication in the treatment dyad.
Convergent evidence thus demonstrates that immediate PCI targets are amenable to intervention. However, such targets are highly proximal to the intervention effort, and in many studies these outcomes are measured within or in very similar contexts to the treatment setting, potentially confounding independence and making possible a simple 'training to the test' result. It is moreover a feature of autism development that the generalisation of acquired skills across contexts is particularly difficult: it cannot be assumed that short-term changes in dyadic interactions of this kind will translate well into more generalised social gains for the child. In this sense, the majority of autism intervention science to date (and the vast majority of published papers) has not really moved beyond what are in effect the equivalent of pre-clinical or early phase studies looking at potential developmental mechanisms, on the (implicit or explicit) assumption that these will go on to effect more generalised autism development and functioning. Even if well done, we can hardly infer from such evidence that a treatment is 'effective for autism': and the (frequent) claims to this effect are inflated and unjustified.
Concurrent child outcomes beyond the dyad
By contrast, measuring child concurrent outcomes beyond the immediate dyadic context ( Figure 1D ) represents a first stage of true generalisation for interventions whose proximal focus is the dyad. It also represents the immediate outcome for therapistchild interventions without parental involvement. An example of such concurrent child social outcome is the behavioural symptoms that define autism disorder itself.
Autism symptoms. The symptoms of autism are most rigorously measured in standardised researcher administered tests of social interaction, which are reliable and can be blind-coded. Because these symptom measures capture the child's social communication with an unfamiliar adult in a context different to the parent-child dyad or treatment setting, they do represent the generalisation of any treatment gains across both context and interaction partner. The most validated of these symptom measures is the Autism Diagnostic Observation Schedule (ADOS-2 (Lord et al., 2000) , which can rate social communication (SA) and repetitive and restrictive behaviour (RRB) dimensions separately or together in a 'Combined Severity Scale' (ADOS CSS). A new related measure from the ADOS originators is the Brief Observation of Social Communication Change (Grzadzinski et al., 2016) designed to be more sensitive to total symptom change in treatment trials. Parent-rated symptom measures such as the Social Communication Questionnaire (Rutter, Bailey, & Lord, 2003) and the Social Responsiveness Scale (Constantino, 2002) are commonly used but are less rigorous because they are unblinded. The specificity of the SRS has also been significantly challenged since it measures such a broad range of behaviours beyond core autism (Kaat & Farmer, 2017; Sturm, Kuhfeld, Kasari, & McCracken, 2017) . Intervention trials highlighted by French and Kennedy (2018) reporting concurrent autism symptom outcomes have had mixed results. Dawson et al., 2010 ; showed no effect on ADOS CSS scores after a 2 year Early Start Denver Model (ESDM) intervention and Fletcher-Watson (Fletcher-Watson et al., 2016) found no effect on BOSCC symptoms with a computer-aided iPad intervention. No parent-rated SRS effect was observed with PRT treatment (Hardan et al., 2015) . On the other hand, significant endpoint reduction in total symptom severity on the ADOS CSS was found after the 1 year preschool PACT intervention where change in Social Communication symptoms alone had failed to reach significance (Green et al., 2010) . It has been harder to show effects on other concurrent outcomes using objective measures. For instance, 2-year intensive ESDM training tested against usual care in 48 children (Dawson et al., 2010) reported significant improvements in IQ (this was carried by improvements in IQ components of receptive and expressive language), but not other child measures. The IQ effects were not sustained at 2-year follow-up (Estes et al., 2015) .
Downstream developmental targets -symptoms and adaptation
There has been a relative lack of developmental follow-on studies after early intervention ( Figure 1E ), although the situation is now beginning to change. The results are somewhat encouraging but have been mixed. On relatively short-term follow-up, Poslawsky et al. (2015) found sustained treatment effect on child initiation of joint attention at 3 months after the video feedback VIPP-AUTI intervention, but not on other measures. Kasari, Paparella, Freeman, & Jahromi, 2008 showed effect on objective language outcomes from the JASPER intervention using the Reynell Developmental Language Scales (RDLS) at 12-month follow-up but this was not replicated in a later study (Kaale, Fagerland, Martinsen, & Smith, 2014) . Chang et al., 2016 measured uncontrolled follow-up of the intervention group only and reported mixed findings. Kasari, Lawton et al. showed maintenance of improvement in their CMM group at 3-month follow-up, but no between-group effect. Other controlled studies that showed between-group endpoint effects on either parent or child dyadic social behaviours do not see them at short or medium-term follow-up (Baranek et al., 2015; Kasari, Siller et al., 2014) .
Four RCTs have however now reported longer-term (>1 year) autism symptom outcomes after preschool intervention. Estes et al. (2015) measured ADOS total score at a mean age of 6 years, 2 years after the end of a 2-year intensive developmental behavioural intervention (ESDM). While there had been no effect on symptoms at trial endpoint, the 21 of 24 children in the intervention group followed up showed greater total and RRB symptom reduction over the follow-up period compared to 18 of 24 followed from the control group. Causal treatment effect inference from these findings is limited however by the lack of intention to treat (ITT) analysis or adjustment for baseline pretreatment variables. Kaale et al. (2014) reported no effect on non-blinded parent-or teacherrated autism symptoms (SCQ) 12 months after a 12-week teacher-mediated JASPER intervention (n = 33) compared to controls (n = 27). In contrast, follow-up of the original PACT trial, 6 years after treatment endpoint, assessed 121 of the original 152 trial participants with core autism at mean age 10.5 years. ITT analysis showed reduction in autism symptom severity (ADOS CSS) at both treatment endpoint (ES 0.64, 95% CI 0.07, 1.20) and follow-up (ES 0.70, 95% CI À0.05, 1.47), resulting in a moderate averaged treatment effect on symptoms over the total period (ES 0.55, 95% CI 0.14, 0.91). Non-blind parent-rated autism symptoms on SCQ (ES 0.40, 95% CI 0.05, 0.77) and repetitive behaviours on RBQ (ES 0.87, 95% CI 0.47, 1.35) also showed comparable improvement at follow up . A similar video-feedback social communication intervention for infants at-risk of autism, implemented between 9 and 14 months of age and followed at one and then 2 years from end of treatment , showed interestingly parallel ITT results, with a significant effect of intervention over the treatment and follow-up period for autism prodromal symptoms (ES = 0.32; 95% CI 0.04, 0.60; p = .026), parental dyadic non-directiveness/synchrony (ES = 0.33; CI 0.04, 0.63; p = .013), and child attentiveness/communication initiation (ES = 0.36; 95% CI 0.04, 0.68; p = .015).
Mediation testing in psychosocial intervention
Only two studies in the extant autism literature have mounted a substantive test of mechanism through a mediation test within an RCT. Gulsrud, Hellemann, Shire, & Kasari (2016) used videotape analysis of the content of therapeutic sessions in the JASPER intervention on key putative active ingredients. There was a possible methods confound in that mediator and primary outcome (joint engagement) were both coded (albeit independently) at endpoint from the same video-material with no midpoint assessment, allowing the possibility of 'reverse causation' in the inference of effect. Nevertheless, the analysis did identify a particular aspect of the therapy (parental 'mirrored pacing') as mediating the joint engagement outcome; which is an important result with generalisable value and points forward to potential further refinements of the therapy procedure. Within the PACT trial, Pickles et al. (2015) , identified a latent midpoint mediator variable using baseline, midpoint and endpoint repeated measures, a method of analysis that also reduces the measurement error intrinsic to observational video coding. Treatment effect on parent synchrony strongly mediated (90%) the change found in child communication initiations with parent, supporting the treatment theory. Both these mediation analyses are thus convergent in identifying similar specific parental interaction behaviours ('mirrored pacing' and 'communicative synchrony') that improve child engagement and communication in the dyadic context. They stand as the clearest mechanism findings to date in autism intervention science and provide important and generalisable information about what are the active components of the therapies in facilitating interaction and child outcomes. Furthermore, the Pickles et al. analysis also showed that it was the change in child dyadic communication initiations with parent (rather than the parental synchrony) that mediated the subsequent change in child autism symptoms with a researcher -thereby demonstrating a causal chain of generalisation of child-acquired skill from the PCI context into a researcher-child interaction. More mechanism tests of this kind will be important going forward.
Summary of psychosocial mechanism targets
Autism particularly impacts social functioning in development. We have seen above that a transactional account of social development and reciprocity in autism, recruiting ideas from social-developmental research in neurotypical populations, has led to a rationale for interventions targeting key aspects of social development in autism. The evidence to date shows that a number of such theoretically based and targeted interventions can indeed reliably improve various aspects of the local dyadic social communication of children with autism, particularly with their caregivers ( Figure 1A -C, Table 1 ). There is less work on whether such dyadic change can produce more generalised impact on concurrent within-child outcomes ( Figure 1D ): there have been positive findings, but the overall evidence is mixed. There is even less work on the crucial issue of long-term developmental outcomes ( Figure 1E ), but some emerging evidence, especially from the PACT trial, that this is possible over the medium to long term. With a developmental disorder like autism, interventions must surely aspire to such long-term effects in order to be convincing as disorder-specific treatments.
Given the convergent evidence that short-term context-specific proximal change is possible using a variety of intervention methods, further replication of this established result on its own is redundant moving forward (although they are the easiest and cheapest designs to carry out!). It is true that mechanism findings from one trial show a causal link between treatment change on child dyadic interaction with caregiver and generalised symptom change across context, and this is encouraging that these proximal changes may (Kasari, Siller 2014) No change with video-feedback (Green, 2015; Poslawsky et al., 2015) or behavioural modelling (Rogers et al., 2012) . Improved on focused playtime intervention (parent coaching and video-modelling) not sustained on FU (Kasari, Siller et al., 2014; Siller et al., 2013 ) Parent intrusiveness/ directiveness
Reduced intrusiveness Poslawsky et al., 2015 ) Parent communicative synchrony 'Child focused dyadic behaviours' (Siller et al., 2013) . DCMA Improved on video-aided intervention Rahman et al., 2016; Siller et al., 2013) Improved and mediates child initiation change on video-aided intervention (Green et al., 2010; Pickles et al., 2015) Child dyadic behaviours
Child dyadic communication/ attentiveness with parent MACI/DCMA Improved in PACT, sustained 6 years after treatment end . Improved in iBASIS, sustained 2 years after treatment end . Improved initiation of JE language and requests in JASPER (Chang et al., 2016) Child initiation of joint attention (IJA)/socially engaged imitation Video coding Effect on child imitation but not on IJA (Landa et al., 2011 ). Improved prompted 'child utterances' with parent (Hardan et al., 2015) Reciprocal dyadic behaviours Dyadic joint engagement, joint attention, joint play Joint engagement (JE) measure JE improved with JASPER (Kasari 2008 , Kaale et al., 2014 Increased joint engagement and play (Shire et al., 2017) No gains in shared affect (Landa et al., 2011) . Short term improved emotional engagement but no follow up effect (Brian et al., 2017) .
No effect on play with parent (Poslawsky et al., 2015) Improved Clinician Global Impression (Hardan et al., 2015 No effect on objective or parent rating (Hardan et al., 2015) . No effect on objective rating but effect on receptive language on parent rating (Green et al., 2010 (Green et al., 2010) . No BOSCC effect from iPAD intervention (Fletcher-Watson et al., 2016) or PRT (SRS) (Hardan et al., 2015 indeed be meaningful in relation to symptoms and generalised adaptation. But such a finding needs replication, and the field now needs larger and more ambitious psychosocial trials that address mechanism, generalisation and the possibilities of long-term developmental and adaptive change, as well as adaptive interventions tailored to patient characteristics and individual response (for instance using sequential multiple assignment randomised 'SMART' trials). Accumulation of such trial evidence will refine approaches and further answer an enduring question; what are the limits to clinically relevant effectiveness of 'environmental' interventions in a condition that is highly heritable and developmentally persistent?
Moving to the level of neural mechanism
The neurodevelopmental context of autism inevitably leads to a consideration of expanded targets for treatment beyond the purely psychosocial into the assumed neural system pathogenesis. No straightforward targets present themselves. The known genetic background of autism shows great heterogeneity and no common final pathways of effect within the neural system linked to the behaviour phenotype have yet been established. At a descriptive level, the large number of genetic variants associated with autism outcomes show convergence on functional networks related to intracellular signalling (see below), neuronal development and axon guidance, and chromatin modification and transcription regulation (Pinto et al., 2014) , but brain localisation of such effects is less established and other findings point to generalised functional aspects such as neural system connectivity (O'Reilly, Lewis, & Elsabbagh, 2017) . Further challenges arise in linking such neuroscience findings to the autism cognitive and behavioural phenotype. Prospective neuroscientific studies of the emergence of autism in the prodrome have suggested some specific risk markers, but as the work has gone on more and more aspects of early neurodevelopment are found to be atypical in autism emergence (Johnson, Gliga, Jones, & Charman, 2015; Szatmari et al., 2016) , replicating perhaps a sense of the heterogeneity in other aspects of autism science.
A promising strategy for limiting this heterogeneity has been to constrain the primary genetic variance by studying monogenic disorders with a high autism expression. As well as simplifying the biological system for study, this strategy has the added advantage that knockout animal models can be bred for detailed biological investigation. There is an inevitable question of whether these 'syndromic models' of ASD in humans actually represent the same phenotype as the idiopathic condition; detailed phenotypic studies suggest they can do (Garg et al., 2015) , but this remains an important question. Some of these syndromic models have indeed demonstrated the searched-for causal chain between genetic variation, cell biology, neural system atypicality and phenotypic behaviour. Thus for instance in animal knock-out models of the monogenic disorder neurofibromatosis 1 (NF1), pharmacological intervention or genetic manipulation can downregulate a cell signalling abnormality directly related to the genetic variation and show consequent effects on improved synaptic function, synaptic protein expression, long-term potentiation and finally rescue of the cognitive and behavioural phenotype (Li et al., 2005; Molosh et al., 2014) . Analogous results have been shown in other syndomic autism conditions such as fragile X (FXS) and tuberous sclerosis complex (TSC). Such animal findings will not necessarily translate into human study (see below) but they provide a proof of principle that intervention in theoretically relevant neural system targets can produce predictable and relevant improvements in relevant behaviour outcomes. This has led to an accelerating effort to study the effect of intervention in humans on a variety of these neural system targets relevant to autism, many but not all of which involve work with monogenic syndromic autism. We thus now review the various neural system mechanisms targeted in these studies, moving in turn from the most 'proximal' in terms of synaptic function; to post-synaptic molecular pathways; to more general brain-growth and neurotropic factors; and finally, to more generalised neural system function reflected in EEG and connectivity measures (see Figure 2 ).
Neurotransmitters/neuromodulatory system targets
Glutamate. Glutamate is the main excitatory neurotransmitter in the brain, exerting its effect through the activation of several receptor subtypes. Fast excitatory synaptic transmission is mediated via ionotropic (AMPA, NMDA and kainite) receptors, whilst modulatory action is exerted through metabotropic G-protein coupled (mGluRs) receptors. The mGluRs play an important role in synaptic plasticity, learning and memory and glutamate signalling is hypothesised to be relevant to aetiology of chronic brain disorders such as schizophrenia and Alzheimers dementia as well as ASD (Uzunova, Hollander, & Shepherd, 2014) . FXS animal model work suggests that exaggerated mGluR signalling induces enhanced hippocampal long-term depression related to the behavioural phenotype (Bear, Huber, & Warren, 2004) . Fenobam, the first mGluR antagonist used in human clinical trials, showed reduced anxiety, hyperarousal and attention in FXS patients in a small (n = 12) single-dose, single-arm open label study (Berry-Kravis et al., 2009 ), but no Phase II studies have been reported, probably due to CNS adverse effects with Fenobam use (Freidmann, Davis, Ciccone, & Rubin, 1980) . Mavoglurant (AFQ056), a structurally novel noncompetitive mGluR5 inhibitor, showed promise in FXS mouse models in rescuing the aberrant dendritic spine morphology and concurrent improvements in the molecular and social behavioural phenotype; however, results from human clinical trials have been less encouraging. Two 12-week, multi-centre phase 2b RCTs of Mavoglurant in 175 adults and 139 adolescents with FXS, showed no significant treatment effects between mavoglurant and placebo on primary endpoints of FXS specific Aberrant Behaviour Checklist (ABC) (Berry-Kravis et al., 2016) . These results suggest that manipulation of the mGluR signalling alone may be insufficient for attenuating the FXS autism phenotype in humans.
Defects in NMDA receptors have been reported in FXS and Rett syndromes although the mechanism is not clearly understood. Memantine, an NMDA receptor antagonist approved for use in Alzheimers disease, improved attentional processes and working memory in patients with Fragile X-associated tremor/ataxia syndrome (Yang et al., 2016) . In FXS, a small open label trial of memantine in six subjects, mean age 18.3 years showed symptom improvement on Clinical Global Impressions (CGI) but no effect on symptom specific rating scales, which included ABC, SRS and ADHD rating scales (Erickson, Mullett, & McDougle, 2009) .
GABA. GABA is the main inhibitory neurotransmitter in the brain, exerting its effect through the GABA A and GABA B postsynaptic receptors. Abnormal GABAergic signalling has been demonstrated in a number of syndromic autism models such as FXS and NF1. The leading hypothesis here is that abnormal GABA signalling leads to an inhibition/excitation imbalance, including dysregulation in protein synthesis. GABAergic signalling is now consequently an important therapeutic target in ASD. In FXS, along with increase in glutaminergic signalling, there is deficiency in GABA receptor expression and GABA mediated inhibition, which has led to the development of therapies aimed to increase GABA mediated inhibition. A double-blind RCT of GABA B agonist arbaclofen in 63 FXS patients aged 6-40 years found significant treatment effects in social behaviours and function (Berry-Kravis et al., 2012) but not on the primary endpoint measure of the Aberrant Behaviour Checklist-irritability subscale. A recent double-blind placebo controlled RCT of Arbaclofen of The state of autism intervention science 125 adolescents/adults (age 12-50 years) and 172 children (age 5-11 years) found no significant treatment effect in either group on the primary outcome measure of FXS specific ABC social avoidance subscale. However, in the child study, significant effects were noted on secondary outcome measures of ABCirritability subscale and parenting stress index, suggesting that younger patients may derive some benefit (Berry-Kravis et al., 2017) . Acamprosate is a mGluR5 receptor antagonist, a GABA A receptor agonist, and has complex actions on NMDA receptors depending on glutamate concentration (Erickson, Early, et al., 2011) . A small open label trial in 12 FXS children aged 6-17 years suggested some improvements in social behaviours, inattention and hyperactivity (Erickson, Mullett, & McDougle, 2010) ; larger studies using Acamprosate in FXS are currently underway and results from trials of other GABA agonists such as ganaxolone are awaited.
More recently, there has been interest in the diuretic Bumetanide, which enhances GABAergic inhibition. In a multi-centre phase 2 RCT (n-= 88, aged 2-18 years), Bumetanide use was associated with significant improvement on parent and clinicianrated autism measures (Lemonnier et al., 2017) ; replication is awaited.
Dopamine. Dopamine plays a crucial role in synaptic plasticity, cognitive functioning and neuropsychiatric pathologies. Interest in the role of Dopamine was stimulated by the observation that Dopamine blockers (anti-psychotics) were effective in treating comorbidities associated with autism such as aggression, hyperactivity and self-injury (Nakamura et al., 2010) . Deficits in dopaminergic functioning have been demonstrated in syndromic models such as FXS, NF1 and TSC. A double-blind cross-over trial of methylphenidate in 15 children with FXS demonstrated that compared to placebo, two-thirds of patients responded well with improvements in social skills, hyperactivity and attention (Hagerman, Murphy, & Wittenberger, 1988 ). An open-label trial of 12 weeks of the partial dopamine D2 agonist Aripiprazole in 12 subjects with FXS showed good tolerance and significant improvement in irritability , though this is not a core autism symptom.
Serotonin. Serotonin (5-hydroxytrytamine, 5-HT)
is a critical modulator of neuronal interaction that supports diverse behaviours and physiological processes including social behaviour, sleep, affective regulation, learning, memory and synaptic plasticity. The serotonergic system was one of the first neurotransmitter systems to be investigated in the pathophysiology of ASD. Several studies have reported elevated levels of platelet serotonin in a third of ASD samples (Cross et al., 2008) ; shortterm dietary depletion of serotonin is linked to increase repetitive behaviours and anxiety in ASD subjects (Veenstra-Vanderweele et al., 2009) ; and mutations in serotonin transporter genes such as SLC29A4 have been linked to ASD symptoms (Adamsen et al., 2014) . Neuroimaging studies using PET have shown significantly lower levels of serotonin synthesis in ASD children compared to controls (Chandana et al., 2005) , particularly in medial frontal cortex, midbrain and temporal lobe areas (Makkonen, Riikonen, Kokki, Airaksinen, & Kuikka, 2008) . Treatment with selective serotonin uptake inhibitors has been shown to have some effect in ameliorating the repetitive/obsessive behaviours in ASD; however, a Cochrane review of nine RCTs found no overall evidence of positive effect of SSRIs on core features (Williams, Brignell, Randall, Silove, & Hazell, 2013) .
Oxytocin. Oxytocin is widely distributed in the CNS
and plays an important role in social recognition, memory, attachment, as well as stereotyped behaviours. It mediates the perinatal excitatory to inhibitory shift of GABA. A number of human studies have examined the effect of oxytocin on social cognition, with mixed results. In a double-blind placebocontrol within-subject design, application of intranasal Oxytocin was associated with attenuated amygdala response to faces regardless of valence (Domes et al., 2007) . In a RCT of 15 adults with ASD, oxytocin was associated with significant reduction in repetitive behaviours in comparison to placebo (Hollander et al., 2003) . However, a number of studies have reported no significant improvement of oxytocin treatment. Dadds et al. (2014) evaluated oxytocin intervention in a double blind RCT in 38 children (age 7-16 years) with ASD administered during parent-child interaction training sessions over four consecutive days and found no treatment effect on social interactional skills or emotional recognition. Similarly, a double blind RCT of Oxytocin nasal spray twice daily in 50 males with ASD (12-18 years) showed no effects on caregiver rated SRS and CGI (Guastella et al., 2015) . One hypothesis for the differences between studies is that individual differences in endogenous oxytocin levels may moderate treatment response. Addressing this issue, a recent RCT of 32 children with ASD investigated the efficacy of 4-week intranasal oxytocin treatment measuring pre-and post-treatment blood oxytocin levels. The study found treatment effects on SRS social abilities confined to those with low baseline oxytocin levels (Parker et al., 2017) .
Signalling pathways targets downstream of neurotransmitter receptors
The MAPK/ERK pathway. Dysregulation of the intracellular Ras/MAPK (mitogen activated protein kinases) signalling pathway is considered a major risk factor for ASD and prominent in functional networks of autism-related genes (Pinto et al., 2014) .
The RAS/MAPK pathway is embedded in a network of other pathways including PI3K and mTOR (see Figure 2 ). Mutations in a number of genes on the Ras pathways have been shown to be associated with ASD (Garg et al., 2013 (Garg et al., , 2017 . NF1 is directly associated with Ras/MAPK pathway overactivity, causing downstream increase in GABA and impairments in synaptic plasticity, making this pathway a rational target for intervention. Statins downregulate the Ras pathway through inhibiting farnesylisation and this rescues the social and behavioural phenotype in NF1 knock-out animal models (Li et al., 2005) . Subsequent translational trials in human NF1 have shown mixed results. Improvements in verbal and nonverbal memory were reported within a 12-week phase 1 observational study of lovastatin in 23 children aged 10-17 years (Acosta et al., 2011) and in a 14-week RCT of lovastatin in 44 10-50 years olds (Bearden et al., 2016) ; an n = 7 case series from the former cohort showed evidence of treatment normalising pseudoresting state functional connectivity in areas of the default mode network (Chabernaud et al., 2012) . Four days of high-dose (200 mg) lovastatin improved synaptic plasticity and phasic alertness, as measured with trans-cranial magnetic stimulation, in a case-controlled study of 11 adults with NF1 (Mainberger et al., 2013) . Larger statin trials, however, have found little effect on cognitive/ behavioural outcomes. A 12-week double-blind, placebo controlled RCT of simvastatin in 62 children with NF1 aged 8-16 found no group differences on the Rey complex figure test (Krab et al., 2008) ; another RCT of simvastatin (84 children aged 8-16 years) found no improvements in cognitive deficits or parent-reported behavioural problems (van der Vaart et al., 2013) ; and a 16-week RCT of lovastatin in 146 8-15 year olds with NF1 found no improvements in paired associate learning (Payne et al., 2016) . In contrast, a recent pilot data-rich RCT (n = 30) of simvastatin in young children with NF1-autism (4.5-10.5 years) studied for the first time the full hypothesised pathway from peripheral MAPK activity, through multiparametric imaging of neural system function to autism-related behaviours (Stivaros et al., 2018) . Indications of possible statin effects towards normalising function were found at all these levels, encouraging the view that detailed mechanism studies of this kind may have potential to be illuminating, but the study needs replication on larger samples. The MAPK/ERK pathway is also implicated in FXS pathogenesis. A 16-week open label trial of Lovastatin in children with FXS suggested significant endpoint improvements on clinician-rated measures (Caku, Pellerin, Bouvier, Riou, & Corbin, 2014) . However, no placebo-controlled trials have so far been reported.
mTOR. Mammalian target of rapamycin (mTOR) is
a key regulator in cellular processes including cell growth, gene expression and synaptic function.
Hyperactivity of the mTOR pathway is associated with several syndromic autism models including TSC, NF1, PTEN, and FXS. Dysregulated mTOR signalling leads to abnormal development of fundamental processes such as axonal and dendritic morphology, synapse formation and cell growth, which have been associated with an ASD phenotype in animal models (Sato, 2016) . Rapamycin is a specific inhibitor of mTOR and in pre-clinical study has improved social behaviour in TSC (Sato et al., 2012) , PTEN-related disorders (Zhou et al., 2009 ) and 15q11-13 duplication (Oguro-Ando et al., 2015) . In TSC, preliminary trials of mTOR inhibitors Sirolimus improved executive function (Davies et al., 2011) and Everolimus reduced seizure frequency and ASD related symptoms on quality of life measures (Krueger et al., 2013) . Based on these initial results, several more TSC RCTs are currently underway testing mTOR pathway inhibitors for neurocognitive and ASD related deficits.
Growth & Neurotrophic factor targets
Deletion/mutation of the SHANK3 gene in PhelanMcDermid syndrome (PMS; also known as 22q13 deletion syndrome) results in reduced expression of scaffolding proteins in the postsynaptic density of excitatory synapses, impairing glutaminergic transmission and synaptic plasticity (Moessner et al., 2007) . PMS is associated with 0.5%-2.0% of all ASD cases. Similarly, loss of function mutations of the X-linked gene MECP2 in Rett syndrome affects the structure and function of synapses at the microcircuit level critical for synaptic transmission and plasticity (Guy, Hendrich, Holmes, Martin, & Bird, 2001) . Recent studies suggest that Insulin-like growth factor-1 (IGF-1) can have a beneficial effect on synaptic development by promoting neuronal cell survival, synaptic maturation and synaptic plasticity (Bozdagi, Tavassoli, & Buxbaum, 2013) . A pilot placebo-controlled double blind RCT using Insulinlike growth factor in nine children with PMS was associated with significant improvements in social impairments and repetitive behaviours (Kolevzon et al., 2014) . In Rett syndrome, an open label phase 1 study of IGF-1 in n = 12 girls with MECP2 showed good safety, tolerability and improvements in behavioural abnormalities (Khwaja et al., 2014) . Studies of IGF-1 in FXS are also underway.
Other drugs such as Minocycline (a tetracycline derivative approved for treatment of acne) have been shown to have neuroprotective effects and upregulate neurotrophic and growth factors in the brain. In FXS animal models, Minocycline has been shown to have an inhibitory effect on matrix metalloproteinase nine activity which is fundamental in modulating hippocampal plasticity. A double-blind placebo controlled cross-over trial of Minocycline in 55 FXS children aged 3.5-16 years over 12 weeks found significant treatment effect on clinician-rated The state of autism intervention science Clinical Global Impression Scale (CGI) but not on any behavioural measures . Furthermore, minocycline use was associated with alteration of event-related potentials in an auditory oddball paradigm in 12 subjects taken from the same trial , possibly suggesting reduced hypersensitivity to auditory stimulation.
Electrophysiological targets
At the more general level of neural system functioning and long-range integration and connectivity, EEG and habituation responses to social stimuli have been investigated as targets for ASD intervention. Linked to underlying social processing and social attention, these can be some of the earliest apparent atypicalities in infants at risk who go on to develop ASD (Johnson et al., 2015; Szatmari et al., 2016) . As an example of EEG as a target of this kind, Jones, Dawson, Kelly, Estes, & Jane Webb, 2017 reported on the EEG outcomes within an RCT of parent-delivered psychosocial 'promoting first relationships' intervention designed to facilitate parent infant interaction and delivered between 9-11 months of infant age. Both at 12-month and 18-month follow-ups they reported increase in social habituation to faces versus objects and greater increase in frontal EEG theta power (Jones et al., 2017) . The study was relatively small with valid data available from 15 or less in the PFR group and 10 or less in the control group over the range of assessments, but the findings provide proof of principle and suggestive results that neurophysiological measures can be impacted by relatively low intensity social communication focused intervention. The results echo a previous study , which studied EEG in 60% of the trial cases at endpoint only after two years intensive ESDM therapy. Although the findings showed no intervention effect across a number of parameters, there was reported increase EEG-theta to social stimuli with faces, which correlated with a parent-reported social communication rating (although not with autism symptoms, IQ, language or adaptive behaviour).
Summary of neural mechanism targets
Studies of syndromic autism have provided a way of identifying causal links from genes to specific molecular and biological pathways and alterations in behavioural outcomes. An underlying hypothesis is that there may be a finite number of common molecular pathways in autism that could act as intervention targets and that treatments thus identified in the context of syndromic ASD could then be applicable to broader idiopathic ASD; thus raising the possibility of a precision medicine approach to autism based on the underlying pathophysiology (Loth, Murphy, & Spooren, 2016) . The work reviewed above reflects the active international effort now in this area, which has already produced some clarification of neural system pathways and encouraging therapeutic leads. These include for instance mTOR inhibitors, statins, oxytocin and pleiotropic growth factors. Despite this, no single treatment has so far been approved for a Phase III trial and there are clearly conceptual as well as practical challenges. Animal experiments cannot fully recapitulate the complexity of higher order cognitive processes in humans. The interventions target a theoretical underlying pathway towards behavioural outcomes, but it is notable that most studies to date have not included detailed measures of this hypothesised pathway and mechanism (Stivaros et al., 2018 is one pilot example that did), and this will be critical in the future. Practical challenges include patient selection, age of treatment onset, dose and duration of treatment, dose-limiting side-effects and lack of CNS biomarkers (Berry-Kravis et al., 2016) . Most human intervention work has been in adolescents or adults and it may be that targeting the developing brain in much younger samples may be crucial. Outcome measurement in these studies -commonly the parent-rated Aberrant Behaviour Checklist (ABC; Aman, 1994) , or the clinician-rated Global Improvement Scale (CGI; Leucht & Engel, 2006) , Table 2 -have also been very different to that in psychosocial research, unfortunately limiting comparability. This is important because to be convincing, treatment studies in this area will need to aspire to the same outcome standards as discussed above for psychosocial research. The need for a common outcomes framework is further discussed below.
Summary
Our focus on target mechanisms for intervention across various pathways to autism outcome aims to give an integrated vantage-point to consider the breadth of current autism intervention research and the continuum of targets across social and biological development. In that context, the targets of the psychosocial approaches to intervention that we have reviewed can be seen as focusing on endpoint pathways nearest in development to autism symptom outcomes. They target child-environment social interaction and child behaviour within developmental processes. We have seen from many studies that targeted psychosocial interventions of various kinds can positively improve over the short-term the most immediate parent-child social communication in development; but the review may have surprised in showing how limited at present is the further evidence of generalised treatment effect. While we do not need more studies to replicate these immediate effects on their own, there are therefore pressing research questions as to how and whether such proximal communication change can be generalised to improve child social functioning beyond the dyad (generalisation across context and person) and sustained long-term within development (generalisation over time). Only with these demonstrations can an intervention be truly persuasive as an autism treatment. We have seen the recently emerging evidence that this is indeed possible, with generalised symptom effects shown for several years following psychosocial intervention. But more replication studies of this kind are needed. The evidence on social communication intervention is now at a stage of maturity where we should be looking to focus on the common mechanisms across therapies that mediate treatment effect, and to combine evidenced effective treatment mechanisms into new implementation approaches combining modular aspects of intervention in clinically useful ways (Marchette & Weisz, 2017) . A recent example has been the integration of social communication intervention with assisted communication (Kasari, Kaiser, et al., 2014) . We do not yet know the limits to developmental improvement that may be possible from psychosocial intervention in this essentially neurodevelopmental disorder. We have then reviewed a new generation of emerging pharmacological treatments that are addressing underlying 'upstream' neural mechanism targets associated with ASD. Most of these are preclinical or early phase trials; but we have suggested above that many of the psychosocial trials described actually have directly analogous status. (It is a sign of the different standards applied to the two domains that, while no one would consider widespread promotion of some of the biological treatments on this basis, the review suggests that some psychosocial interventions with similar or lower levels of evidence are widely implemented. Even if the downside risks associated with psychosocial treatments are felt to be less, we still argue that this situation is highly unsatisfactory and will hamper progress).
One question for the future is whether there may be synergy between psychosocial treatments of demonstrated effect and emerging interventions targeting biological and neural system targets. No substantive trial of such synergy has yet been published and this remains an aspiration. How might such synergy work? We must imagine the developing brain in transaction with the quality of its social experience. A great advantage of reviewing biological and psychosocial treatments together is to provide such a perspective. Understanding the complex transactional pathways to social impairment and development in this way will work against a reductionism that may follow from linear translational models from animal work. The process of synergy might be simply additive on treatment outcome. However, there might be multiplicative effects through for instance: (i) timely neural system enhancement allowing enhanced response to psychosocial intervention, for instance the hypotheses that oxytocin administration might help social learning in therapy has been tested in pilot studies; (ii) psychosocial intervention altering neural system targets in a way that could be adjunctive to biological intervention or promoting sustained effects on development. Preliminary evidence is provided above of psychosocial intervention impacting EEG markers of social processing at least in the short term. Understanding the continuities and transactions of mechanism between these psychosocial and biological targets will help progress, clinical work and a coherent sense of the task.
Common methods of process and outcome measurement across biological and psychosocial Insulin-like growth factor 1(IGF-1) (Kolevzon et al., 2014) , n = 9, double blind cross-over study design studies will be important going forward -something that has not so far happened; the two fields having different traditions of outcome measurement. Some argue that autism symptom outcomes are the most appropriate metric since they define the disorder and can be measured blind. However, methods of symptom measurement have unfortunately to date differed between psychosocial and biological intervention domains; psychosocial trials using ADOS which addresses autism behavioural symptoms with high external validity, biological trials using ABC or CARS which have less specificity for diagnostic symptoms and external validity. Others argue that more 'real world' adaptive assessments are appropriate, although there is a lack of blinded assessments of this kind. There are no appropriate assessments as yet of child and parent quality of life in autism, which could help look at wider outcome (Jonsson et al., 2017; McConachie et al., 2015) . Choice of assessment relates also to an emerging debate on the appropriate ultimate aims for intervention in autism; an interesting issue that extends beyond the solely professional or scientific arena. Applying the '4 P's' approach to autism intervention (Insel, 2007 (Insel, , 2014 will involve a Participatory approach whereby experts-by-experience of autism should join with interventionists in thinking about the most beneficial intervention outcomes; a Personalised approach that will be facilitated by quality intervention science that investigates both mechanism and effect moderation; a Predictive approach that follows intervention effects downstream and be shown to change things that are theoretically important for developmental science -but also for families and individuals; and Pre-emptive in the timeliness of such intervention at a point in development where it may do most benefit. The fact that this has added urgency now is a testament to the advances that have been made in developing potentially effective interventions; a success that necessitates wide dialogue between basic science, interventionists, ethicists, families and the wider autism community, and which also holds real promise for the developmental outcomes of children with an autism development.
